

HYDROLIFT® ACTION – GLOBAL TREATMENT WITH ALIAXIN®



DR. GABRIEL B. SIQUIER DAME TO is an Aesthetic Medicine Practitioner practicing in Amsterdam, The Netherlands

contact: info@dametoclinic.com

Gabriel B. Siquier Dameto discusses the benefits of using IBSA's latest soft tissue fillers, Aliaxin® EV and Aliaxin® SR, to increase hydration and volume in the face

Many of the changes in facial structure we experience through the ageing process are the result of the combined effects of atrophy and loss of facial fullness, progressive bone resorption, decreased tissue elasticity, and gravity. The gradual loss of underlying soft tissue support and fullness is responsible for the descent of soft tissue and relative excess of facial skin.

Rather than the correction of individual defects, we are now seeing a move towards a global treatment, such as increasing the volume of the middle third or remodelling the lower third for complete facial balance. Hydration is another key element to the overall youthful look.

If we look at different ways to assess beauty like the golden ratio, the beauty triangle, or the ogee curve, we find that increasing cheek volume and enhancing malar projection are important focus points of facial rejuvenation.

Aliaxin® EV and Aliaxin® SR

Aliaxin® EV (Essential Volume), the latest addition to the Aliaxin® filler line of products from IBSA Farmaceutici Italia, is a monophasic hyaluronic acid (HA) gel with the presence of two different molecular weights: 1000kDa and 2000kDa.

With two different molecular weights, Aliaxin® EV is able to work

on different HA receptors, utilising a variety of known mechanisms to regenerate skin tissue. This gives this new filler an advantage from both a biological and a mechanical point of view. A high molecular weight HA fills larger spaces, while a low molecular weight HA fills smaller spaces, thus achieving a more well rounded filling effect.

Importantly, the use of Aliaxin® EV

stimulating (biological stimulation action on fibroblasts), and lifting (mechanical filling and lifting action) a multitude of skin defects.

Aliaxin® SR, a monophasic gel containing HA of three distinct molecular weights (500kDa, 1000kDa, 2000kDa), allows physicians to realise superb lifting of cutaneous wrinkles and promotion of neocollagenesis, with the end goal

“If we look at different ways to assess beauty like the golden ratio, the beauty triangle, or the ogee curve, we find that increasing cheek volume and enhancing malar projection are important focus points of facial rejuvenation.”

is very safe and manageable. In keeping with most volumising fillers, it is indicated for use at the supraperiosteal layer and deep tissue, but Aliaxin® EV can also be injected at the deep or mid-dermal level with no adverse effects. Therefore, it is safe for use throughout the malar region. The smoothness of the gel reduces the occurrence of side-effects like bruising and swelling, as well as the risk of overcorrection.

Aliaxin® SR (Shape and Restore) has been uniquely formulated with both natural and cross-linked HA according to IBSA Italia's pioneering Hydrolift® Action concept, resulting in an all-around anti-ageing product especially suited for hydrating (owing to its hygroscopic capacity),

of biostructuring. The additional 10% presence of natural HA grants a significant anti-ageing and hydrating effect, taking only a few weeks after treatment for maximum results to be seen.

Combination treatment for midface rejuvenation

Complete facial rejuvenation cannot be achieved using just one type of filler. Considering the different anatomical and morphological properties of the various areas of the face, a physician must employ a gamut of products specified for each region and designed for a specific outcome.

Though some practitioners may be apprehensive about injecting



Hyaluronic Acid Experts

“The combined use of Aliaxin® EV and Aliaxin® SR allows the physician to join the volumising effect with midface facial remodelling, resulting in a balanced facial structure and an overall rejuvenated effect.”

larger volumes of filler, by using a double layer technique with the combination of Aliaxin® EV and Aliaxin® SR a physician can restore the volume of the middle third of the face with an effective and natural result.

To enhance the malar prominence we use a deep layer of Aliaxin® EV. Injections are made with a 25G needle inserted at a 90° angle until immediately above the periosteum, using a pyramids technique with base on periosteum, and a volume of 0.1-0.2mL per injection point. Usually 0.5-1mL of Aliaxin® EV per hemi-face is used with a maximum of 2mL. We start in the medial region of the nasojugal crease and extend laterally as seen in *Figure 1* (blue points).

Aliaxin® SR is used at a more superficial layer, in this case with microcannula and a fanning technique with entry point from the lateral zygomatic bone, indicated with orange lines in *Figure 1*. Usually 0.5-1mL of Aliaxin® SR per hemi-face is used with a maximum of 2mL. In many patients we also fill the area adjacent to the lateral canthus. We massage the injected area as needed at the time of the visit, but do not require patients to massage at home.

For a complete midface rejuvenation, a combination of Aliaxin® EV and Aliaxin® SR can be

used: injected at a deep level, Aliaxin® EV enhances the malar area while Aliaxin® SR injected with a microcannula at the middle dermis promotes neocollagenesis and biostructuring with anti-ageing and hydrating effects.

Conclusions

Aliaxin® EV is one of the most reliable volumising HA-based fillers on the market, in terms of efficacy, safety and durability. Aliaxin® SR, with its stimulating biological action, complements the filling treatment with an anti-ageing action. The combined use of Aliaxin® EV and Aliaxin® SR allows the physician to join the volumising effect with midface facial remodelling, resulting in a balanced facial structure and an overall rejuvenated effect. 

► Further information

www.ibsaderma.com;
info@ibsaderma.com

► Visit us at **IMCAS Paris** booth A7 and symposium no. 15, Friday January 30, 11:30-12:30 pm




Figure 1 Blue points indicate Aliaxin® EV injection sites, orange lines indicate Aliaxin® SR injection sites.



Figure 2 (A) Before treatment, and (B) 1 month after treatment